Accurate Diagnostic: The promise of NGS

Accurate Diagnostic: The promise of NGS


Next-Generation Sequencing (NGS) has significantly impacted cancer diagnostics, enabling the identification of novel cancer mutations, personalized treatment, and improved clinical diagnosis. NGS has been widely applied in clinical oncology for cancer prevention, diagnosis, and treatment. It has facilitated the identification of novel and rare somatic mutations in various cancers, including blood cancer, renal cell carcinoma, and lung cancer. 

Additionally, NGS has been used to sequence known cancer genes, identify genetic susceptibility, and define therapeutic vulnerabilities of cancer, leading to its rapid translation from discovery to clinical platform. In the context of advanced non-small cell lung cancer, NGS using circulating tumor DNA has shown high diagnostic accuracy, making it a reliable alternative for guiding patients to the right treatment based on their molecular profile. The implementation of NGS in a clinical setting offers exciting possibilities, such as rapidly screening numerous gene targets at minimal cost and revolutionizing cancer treatment through the emergence of small molecule inhibitors and antibodies against druggable gene targets.

NGS's ability to assess multiple genes in a single assay eliminates the need for ordering multiple tests to identify the causative mutation, making it a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors in oncology.


ONCOTARGET: Comprehensive Genomic Profiling Panel for Cancer Detection
ONCOTARGET is a comprehensive genomic profiling panel designed for cancer detection. It consists of 1,229 probes targeting 10 oncogenes and the TP53 gene. Clinicians can use this kit to guide treatment decisions based on genotyping results from various sample types, including fresh or frozen tumors, FFPE tissues, and liquid samples. The panel’s cost-effectiveness and accuracy make it a valuable tool in oncology research and patient care.

LymphoSign Test-Kit : A fine classification of non-Hodgkin's lymphomas
  The LymphoSign Kit, plays a crucial role in establishing accurate diagnoses and treatment plans for non-Hodgkin’s lymphoma. Leveraging RNA expression levels from over 130 relevant gene markers, this state-of-the-art method provides valuable insights into disease progression. Its simple, fast protocol and suitability for challenging samples make it a powerful tool in non-Hodgkin’s lymphoma research and patient care .

 Sarcoma diagnostic in a single reaction

The SarcomaFusion test detects fusion transcripts in sarcomas. These transcripts, associated with specific subtypes and targeted treatments, are crucial for patient care. Using patented ligation-dependent PCR technology, the test simplifies diagnostics and enhances our understanding of sarcoma biology. Its rapid protocol and robustness make it a valuable tool in oncology.